Abrégé

in vivo in vivo half-life and methods for making the same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

Classes IPC  ?

• A61K 38/22 - Hormones
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/64 - Relaxines
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

ss alpha subunit (CAGαS), such that the CAGPCR and/or CAGαS is expressed in the immune cell.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

Relaxin-2 exhibits strong antifibrotic activity. However, due to the limited in vivo half-life of relaxin, treatment of patients has to be repeated every 14 to 21 days, whereby compound administration has to be performed as a continuous infusion for at least 48 hours. Further, the synthesis of relaxin-2 is difficult. Due to the low solubility of the B-chain and the requirement for the laborious, specific introduction of cysteine bridges between A and B-chains, yields of active peptide obtained by these methods are extremely low. There is a need for an engineered relaxin-2 analog with greater half-life and greater ease in production. The present disclosure provides relaxin-2 fusion protein analogs with enhanced in vivo half-life and methods for making the same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

Classes IPC  ?

• A61K 38/22 - Hormones
• C07K 14/64 - Relaxines
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Produits et services

Biotechnology and pharmaceutical testing, research, development, and analysis; pharmaceutical, biomedical, and biological therapeutic research and services; pharmaceutical research and development; biological research services; research and development services in the pharmaceutical and biopharmaceutical fields; research and development services in the pharmaceutical and biopharmaceutical fields, namely, in the field of technologies related to proteins and G-protein-coupled receptors (GPCRs); research services in biology fields; pharmaceutical research services in biological drug discovery and development; pharmaceutical research and development services for identifying lead biologics; research and development services in the creation of libraries or collections of biologicals; pharmaceutical research and development in the nature of research, creation, and development of biological drug targets for non-medical scientific screening purposes; pharmaceutical research, analysis, and examination for identification of biologics through automated screening processes; laboratory research, screening, evaluation, and development of biologics; research, studies, and development in the field of pharmaceuticals and biologics; research and development services in biological pharmaceutical development; medical and pharmacological research services; analysis and measurement of pharmaceutical, biomedical, and biological molecules and characteristics; bioanalysis services; biochemical analysis; research and development of medicines; research and development services in the field of antibodies and small proteins; research and development services in the field of antibody and small protein technology; research relating to molecular sciences; research relating to pharmaceuticals; scientific and pharmaceutical research and development, namely, use of in silico, in vitro, and in vivo methods and procedures for biologic, drug, and target production, manipulation, screening, selection, and assaying; provision of information, advisory services, and consultancy relating to the aforesaid services